Kingsoft Cloud Holdings Limited vs Sanofi SA — how do they compare? Kingsoft Cloud Holdings Limited trades at $11.66 (market cap $3.53B), while Sanofi SA trades at $43.54 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 29.5× Kingsoft Cloud Holdings Limited's market cap, and Sanofi SA pays a 5.55% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals.
| KC | SNY | |
|---|---|---|
Market Cap | $3.53B | $104.30B |
Sector | Technology | Health |
52-Week High | $18.21 | $52.34 |
52-Week Low | $8.58 | $41.33 |
Enterprise Value | $3.84B | $124.19B |
Dividend Yield | — | 5.55% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Trailing returns across standard periods
Latest headlines on both assets
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →